儿童难治性癫痫的医用大麻：综述
Medical Cannabis for Intractable Epilepsy in Childhood: A Review.
作者信息
Ben-Zeev Bruria
机构信息
Pediatric Neurology Department, The Edmond and Lilly Safra Pediatric Hospital, Sheba Medical Center, Tel Hashomer, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
出版信息
Rambam Maimonides Med J. 2020 Jan 30;11(1):e0004. doi: 10.5041/RMMJ.10387.
Abstract
In recent years, cannabis has been gaining increasing interest in both the medical research and clinical fields, with regard to its therapeutic effects in various disorders. One of the major fields of interest is its role as an anticonvulsant for refractory epilepsy, especially in the pediatric population. This paper presents and discusses the current accumulated knowledge regarding artisanal cannabis and Epidiolex®, a United States Food and Drug Administration (FDA)-approved pure cannabidiol (CBD), in epilepsy management in pediatrics, by reviewing the literature and raising debate regarding further research directions.
摘要
近年来，大麻因其在各种疾病中的治疗作用，在医学研究和临床领域都越来越受到关注。其中一个主要的关注领域是其作为难治性癫痫抗惊厥药物的作用，尤其是在儿科人群中。本文通过回顾文献并引发关于进一步研究方向的讨论，介绍并讨论了目前关于手工制作大麻和美国食品药品监督管理局（FDA）批准的纯大麻二酚（CBD）药物Epidiolex®在儿科癫痫治疗中的积累知识。
相似文献
1
Medical Cannabis for Intractable Epilepsy in Childhood: A Review.
Rambam Maimonides Med J. 2020 Jan 30;11(1):e0004. doi: 10.5041/RMMJ.10387.
2
Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Epilepsy Behav. 2018 Mar;80:240-246. doi: 10.1016/j.yebeh.2018.01.026. Epub 2018 Feb 9.
3
Medical Marijuana in the Pediatric Population With Epilepsy-What You Should Know.
J Pediatr Health Care. 2019 Nov-Dec;33(6):626-632. doi: 10.1016/j.pedhc.2019.03.002. Epub 2019 Jun 1.
4
Cannabis for the Treatment of Epilepsy: an Update.
Curr Neurol Neurosci Rep. 2018 Sep 8;18(11):73. doi: 10.1007/s11910-018-0882-y.
5
Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects.
F1000Res. 2019 Feb 28;8. doi: 10.12688/f1000research.16515.1. eCollection 2019.
6
The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law.
Epilepsy Behav. 2017 May;70(Pt B):288-291. doi: 10.1016/j.yebeh.2016.11.021. Epub 2017 Feb 4.
7
Medical Cannabis in Children.
Rambam Maimonides Med J. 2020 Jan 30;11(1):e0003. doi: 10.5041/RMMJ.10386.
8
Cannabidiol as potential treatment in refractory pediatric epilepsy.
Expert Rev Neurother. 2016;16(1):17-21. doi: 10.1586/14737175.2016.1121098. Epub 2015 Dec 9.
9
Cannabinoids in treatment-resistant epilepsy: A review.
Epilepsy Behav. 2017 May;70(Pt B):341-348. doi: 10.1016/j.yebeh.2016.11.012. Epub 2017 Feb 8.
10
CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.
Seizure. 2016 Feb;35:41-4. doi: 10.1016/j.seizure.2016.01.004. Epub 2016 Jan 6.
引用本文的文献
1
Use of Cannabis-Based Medical Products for Pediatric Health Conditions: A Systematic Review of the Recent Literature.
Med Cannabis Cannabinoids. 2024 Dec 10;7(1):257-267. doi: 10.1159/000542550. eCollection 2024 Jan-Dec.
2
New Pharmacological Therapies in the Treatment of Epilepsy in the Pediatric Population.
J Clin Med. 2024 Jun 18;13(12):3567. doi: 10.3390/jcm13123567.
3
Real-World Evidence of Factors Affecting Cannabidiol Exposure in Children with Drug-Resistant Developmental and Epileptic Encephalopathies.
Pharmaceutics. 2023 Aug 10;15(8):2120. doi: 10.3390/pharmaceutics15082120.
4
Clinical Outcome Data of Children Treated with Cannabis-Based Medicinal Products for Treatment Resistant Epilepsy-Analysis from the UK Medical Cannabis Registry.
Neuropediatrics. 2023 Jun;54(3):174-181. doi: 10.1055/a-2002-2119. Epub 2022 Dec 20.
5
School Nurse Perspectives of Medical Cannabis Policy in K-12 Schools: An Exploratory Descriptive Study.
J Sch Nurs. 2024 Dec;40(6):596-607. doi: 10.1177/10598405221136288. Epub 2022 Nov 14.
6
Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis.
Sci Rep. 2021 Dec 6;11(1):23462. doi: 10.1038/s41598-021-02770-6.
7
Cardiac Transplantation and the Use of Cannabis.
Life (Basel). 2021 Oct 9;11(10):1063. doi: 10.3390/life11101063.
本文引用的文献
1
The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study.
Epilepsy Behav. 2019 Sep;98(Pt A):233-237. doi: 10.1016/j.yebeh.2019.07.007. Epub 2019 Aug 5.
2
Effects of cannabidiol on brivaracetam plasma levels.
Epilepsia. 2019 Jul;60(7):e74-e77. doi: 10.1111/epi.16071. Epub 2019 Jun 18.
3
Potential Clinical Benefits of CBD-Rich Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis.
Front Neurol. 2018 Sep 12;9:759. doi: 10.3389/fneur.2018.00759. eCollection 2018.
4
5
Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.
Epilepsia. 2018 Aug;59(8):1540-1548. doi: 10.1111/epi.14477. Epub 2018 Jul 12.
6
Quality Traits of "Cannabidiol Oils": Cannabinoids Content, Terpene Fingerprint and Oxidation Stability of European Commercially Available Preparations.
Molecules. 2018 May 20;23(5):1230. doi: 10.3390/molecules23051230.
7
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631.
8
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
Neurology. 2018 Apr 3;90(14):e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14.
9
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet. 2018 Mar 17;391(10125):1085-1096. doi: 10.1016/S0140-6736(18)30136-3. Epub 2018 Jan 26.
10
Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome.
Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11229-11234. doi: 10.1073/pnas.1711351114. Epub 2017 Oct 2.
Zotero 插件